Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Amplia Therapeutics ( (AU:ATX) ) is now available.
Amplia Therapeutics has released its 2025 Corporate Governance Statement, which outlines the company’s adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The statement emphasizes the board’s role in overseeing the company’s strategic direction, enhancing shareholder value, and ensuring effective management and accountability systems. This governance framework is crucial for maintaining investor confidence and supporting Amplia’s strategic initiatives in advancing its pharmaceutical pipeline.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for the treatment of cancer and fibrosis. The company focuses particularly on fibrotic cancers such as pancreatic and ovarian cancer, and FAK’s role in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 1,677,450
Technical Sentiment Signal: Sell
Current Market Cap: A$19.4M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.